

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 2, 2022**

**Blonder Tongue Laboratories, Inc.  
(Exact Name of registrant as specified in its charter)**

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>1-14120</b> (Commission File Number)	<b>52-1611421</b> (I.R.S. Employer Identification No.)
<b>One Jake Brown Road, Old Bridge, New Jersey</b> (Address of principal executive offices)		<b>08857</b> (Zip Code)

**Registrant's telephone number, including area code: (732) 679-4000**

**Not Applicable  
(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Common Stock, par value \$.001</b>	<b>BDR</b>	<b>NYSE American</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 2, 2022, the board of directors (the “Board”) of Blonder Tongue Laboratories, Inc. (the “Company”), based on the recommendation of the Compensation Committee of the Board, approved certain changes to the compensation to be received by directors for the first half of 2022. Instead of continuing to compensate directors through a combination of cash payments and common stock grants as in 2021, during the first six months of 2022 directors will be compensated for their service on the Board and committees of the Board through grants of options to purchase shares of the Company's common stock. The options, which will be granted under the Blonder Tongue 2016 Director Equity Incentive Plan (“2016 Plan”), will vest on September 30, 2022, have a 10 year term, be granted as of the fifth trading day after the trading day on which the Company’s earnings for the year ended December 31, 2021 have been released to the public, and have an exercise price equal to the fair market value (as defined in the 2016 Plan) on the date of grant. The Board intends to reevaluate director compensation in advance of July 1, 2022.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BLONDER TONGUE LABORATORIES,  
INC.

By: /s/ Eric Skolnik

Eric Skolnik  
Senior Vice President and Chief Financial  
Officer

Date: February 4, 2022

---